Literature DB >> 11836403

trans-Complementation rescue of cyclophilin A-deficient viruses reveals that the requirement for cyclophilin A in human immunodeficiency virus type 1 replication is independent of its isomerase activity.

Andrew C S Saphire1, Michael D Bobardt, Philippe A Gallay.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) requires the incorporation of cyclophilin A (CypA) for replication. CypA is packaged by binding to the capsid (CA) region of Gag. This interaction is disrupted by cyclosporine (CsA). Preventing CypA incorporation, either by mutations in the binding region of CA or by the presence of CsA, abrogates virus infectivity. Given that CypA possesses an isomerase activity, it has been proposed that CypA acts as an uncoating factor by destabilizing the shell of CA that surrounds the viral genome. However, because the same domain of CypA is responsible for both its isomerase activity and its capacity to be packaged, it has been challenging to determine if isomerase activity is required for HIV-1 replication. To address this issue, we fused CypA to viral protein R (Vpr), creating a Vpr-CypA chimera. Because Vpr is packaged via the p6 region of Gag, this approach bypasses the interaction with CA and allows CypA incorporation even in the presence of CsA. Using this system, we found that Vpr-CypA rescues the infectivity of viruses lacking CypA, either produced in the presence of CsA or mutated in the CypA packaging signal of CA. Furthermore, a Vpr-CypA mutant which has no isomerase activity and no capacity to bind to CA also rescues HIV-1 replication. Thus, this study demonstrates that the isomerase activity of CypA is not required for HIV-1 replication and suggests that the interaction of the catalytic site of CypA with CA serves no other function than to incorporate CypA into viruses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836403      PMCID: PMC135933          DOI: 10.1128/jvi.76.5.2255-2262.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction.

Authors:  E K Franke; J Luban
Journal:  Virology       Date:  1996-08-01       Impact factor: 3.616

2.  Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.

Authors:  T R Gamble; F F Vajdos; S Yoo; D K Worthylake; M Houseweart; W I Sundquist; C P Hill
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

3.  Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions.

Authors:  J Luban
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

4.  Functional association of cyclophilin A with HIV-1 virions.

Authors:  M Thali; A Bukovsky; E Kondo; B Rosenwirth; C T Walsh; J Sodroski; H G Göttlinger
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

5.  Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization.

Authors:  J Colgan; H E Yuan; E K Franke; J Luban
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells.

Authors:  U von Schwedler; J Song; C Aiken; D Trono
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

8.  Crystal structures of cyclophilin A complexed with cyclosporin A and N-methyl-4-[(E)-2-butenyl]-4,4-dimethylthreonine cyclosporin A.

Authors:  H Ke; D Mayrose; P J Belshaw; D G Alberg; S L Schreiber; Z Y Chang; F A Etzkorn; S Ho; C T Walsh
Journal:  Structure       Date:  1994-01-15       Impact factor: 5.006

9.  Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions.

Authors:  A Billich; F Hammerschmid; P Peichl; R Wenger; G Zenke; V Quesniaux; B Rosenwirth
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

10.  Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41.

Authors:  G Roderiquez; T Oravecz; M Yanagishita; D C Bou-Habib; H Mostowski; M A Norcross
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

View more
  9 in total

Review 1.  Plunder and stowaways: incorporation of cellular proteins by enveloped viruses.

Authors:  Réjean Cantin; Sylvie Méthot; Michel J Tremblay
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Cyclophilin a plays distinct roles in human immunodeficiency virus type 1 entry and postentry events, as revealed by spinoculation.

Authors:  Andrew C S Saphire; Michael D Bobardt; Philippe A Gallay
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A.

Authors:  Yuan Li; Alak Kanti Kar; Joseph Sodroski
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

4.  Reconstitution of retroviral fusion and uncoating in a cell-free system.

Authors:  Shakti Narayan; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

5.  Chimeric human immunodeficiency virus type 1 (HIV-1) virions containing HIV-2 or simian immunodeficiency virus Nef are resistant to cyclosporine treatment.

Authors:  Mahfuz Khan; Lingling Jin; Ming Bo Huang; Lesa Miles; Vincent C Bond; Michael D Powell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Treatment of human immunodeficiency virus type 1 virions depleted of cyclophilin A by natural endogenous reverse transcription restores infectivity.

Authors:  Mahfuz Khan; Minerva Garcia-Barrio; Michael D Powell
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  The host-pathogen interaction of human cyclophilin A and HIV-1 Vpr requires specific N-terminal and novel C-terminal domains.

Authors:  Sara M Ø Solbak; Victor Wray; Ole Horvli; Arnt J Raae; Marte I Flydal; Petra Henklein; Peter Henklein; Manfred Nimtz; Ulrich Schubert; Torgils Fossen
Journal:  BMC Struct Biol       Date:  2011-12-20

8.  Enzymes: An integrated view of structure, dynamics and function.

Authors:  Pratul K Agarwal
Journal:  Microb Cell Fact       Date:  2006-01-12       Impact factor: 5.328

9.  Fluorescent protein-tagged Vpr dissociates from HIV-1 core after viral fusion and rapidly enters the cell nucleus.

Authors:  Tanay M Desai; Mariana Marin; Chetan Sood; Jiong Shi; Fatima Nawaz; Christopher Aiken; Gregory B Melikyan
Journal:  Retrovirology       Date:  2015-10-29       Impact factor: 4.602

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.